Form 8 (DD) – Olivier Bohuon
FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR […]
Rosehill Resources Inc. Provides 2019 Guidance Along With Operational Update
HOUSTON, Dec. 20, 2018 (GLOBE NEWSWIRE) — Rosehill Resources Inc. (“Rosehill” or the “Company”) (NASDAQ: ROSE, ROSEW, ROSEU) today announced […]
Nabriva Therapeutics Submits New Drug Applications to U.S. Food and Drug Administration for Intravenous and Oral Lefamulin to Treat Community-Acquired Bacterial Pneumonia in Adults
DUBLIN, Ireland, Dec. 20, 2018 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the […]
The Tile Shop Names Cabell Lolmaugh as Director and CEO
MINNEAPOLIS, Dec. 20, 2018 (GLOBE NEWSWIRE) — Tile Shop Holdings, Inc. (Nasdaq: TTS) (the “Company”), a specialty retailer of natural […]
Apellis Pharmaceuticals Provides Update on Its Phase 3 Program for Patients with Geographic Atrophy
Phase 3 geographic atrophy program enrollment timeline currently unchanged; program enrollment is expected to restart in Q2 2019 and enrollment […]
Amicus Therapeutics Announces First Patient Dosed in Phase 3 PROPEL Pivotal Study of AT-GAA in Patients with Pompe Disease
Global Study to Assess AT-GAA Compared to Standard-of-Care Enzyme Replacement Therapy (ERT) over 52 Weeks CRANBURY, N.J., Dec. 20, 2018 […]
Form 8 (DD) – Gail Fosler
FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR […]
Form 8 (DD) – Albert Stroucken
FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR […]
LGI Homes Opens Large-Scale Development in Houston Market
Freeman Ranch boasts multiple amenities and a desirable location KATY, Texas, Dec. 20, 2018 (GLOBE NEWSWIRE) — LGI Homes, Inc. […]
Supernus Announces Positive Results from Phase III Study For SPN-812 in Adolescents with ADHD
Met primary endpoint with robust statistical significance Third positive Phase III study for SPN-812 in patients with ADHD Showed efficacy […]
